The deadline has been moved to Monday 7/10!!

Congratulations to our fellow Anshumi Desai who is going to present our work in Yokohama at ASCO Breakthroughs ASBrS Society of Surgical Oncology UHealthSurg Edu Fund Jackson Health System UM/JMH General Surgery

So proud of our two amazing graduating fellows!! ⁦Anshumi Desai⁩ ⁦Alexis R. Narvaez-Rojas, M.D. (DrN)⁩ ⁦Mecker G Möller MD FACS MAMSE⁩ ⁦Jackson Health System⁩ ⁦UM/JMH General Surgery⁩ ⁦Sylvester Comprehensive Cancer Center⁩ ⁦Society of Surgical Oncology⁩ ⁦ASBrS⁩

Honored to have hosted 2 SLYMPHA fans over last 2 weeks. Dr Jay R. Anam from Mumbai and Jamila Alazhri جميلة خالد الأزهري from Damam. The club is growing internationally!! UHealthSurg Edu Fund Sylvester Comprehensive Cancer Center Jackson Health System ASBrS

Watch as Dr. Eli Avisar, breast surgical #oncologist and #lymphedema specialist, lists three things you didn’t know about lymphedema. | Instagram instagram.com/reel/Cyy_A8QrP…

Join us in congratulating Dr. Anshumi Desai as one of the recipients of Panchi’s Postdoctoral Prize. 🙌🎉 “This #award signifies the strength of our collaborative #team, guided by inspiring #mentors and supported by dedicated colleagues and #medical #students,” said Dr. Desai.

Great to meet potential applicants at “meet and greet” Society of Surgical Oncology ASBrS Jackson Health System Sylvester Comprehensive Cancer Center UHealthSurg Edu Fund UM/JMH General Surgery #SSO24

Great Melanoma debate yesterday. Lots learned from breast NAC, node tagging, targeted ALND and lymphedema preventive approaches. Time for SLYMPHA to be expanded to Melanoma colleagues! Society of Surgical Oncology European Society of Surgical Oncology (ESSO) Annals of Surgery ASBrS Jackson Health System Sylvester Comprehensive Cancer Center UHealthSurg Edu Fund

From SABCS low BMI remains essential for breast cancer prevention. Weight loss may be slow to lower breast cancer risk

TARGIT IORT Under Threat, Again Recently we were challenged by American Society of Therapeutic Radiation Oncology proposing a change in policy that could lead to the loss of insurance coverage for Targeted Intraoperative Radiotherapy (TARGIT) for early-stage breast cancer.

We are now facing the same challenge from the American Society of Breast Surgeons which at this moment is considering adopting a policy that will likely lead to many women losing access to Targeted Intraoperative Radiotherapy.

Although breast surgeons have generally been among the strongest advocates for IORT, the leaders of the American Society of Breast Surgeons are likely being influenced by their radiation oncology colleagues who have a vested financial interest in opposing IORT.

The bottom line (literally!) is that radiation oncologists make much less money doing IORT compared to traditional radiation. Although they make a lot of fuss about a 2-4% difference in IORT effectiveness compared to traditional radiation, the real elephant in the room is $$$.

Here's why targeted IORT needs to be protected: IORT is a single dose radiation treatment administered in < 30 minutes at the time of lumpectomy. It has less radiation exposure to skin, heart and lungs,eliminates the financial burden of daily treatments, with superior cosmesis

Critics of TARGIT complaint that targeted IORT has a higher recurrence rate compared to traditional whole breast radiation. Although some forms of IORT have been shown to have a 2-4% higher recurrence rate compared to whole breast radiation, that is NOT the case for TARGIT.

Furthermore this stance completely disregards patient choice in healthcare decision-making How can you help? Let the American Society of Breast Surgeons know your opinion lnkd.in/e4NYyBzB Comments are due by end of day June 9th, 2025. Sorry for the short timeline.